Patents by Inventor Martin Ambler

Martin Ambler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused thiazolopyrimidine derivatives as MNKs inhibitors
    Patent number: 11136338
    Abstract: The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably. Alzheimer's disease.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: October 5, 2021
    Assignee: LIFEARC
    Inventors: Jon James Winter-Holt, Edward Giles Mciver, Martin Ambler, Stephen Lewis, Joanne Osborne, Kayleigh Webb-Smith
  • Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors
    Publication number: 20200247822
    Abstract: The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably. Alzheimer's disease.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 6, 2020
    Inventors: Jon James Winter-Holt, Edward Giles Mciver, Martin Ambler, Stephen Lewis, Joanne Osborne, Kayleigh Webb-Smith
  • Fused thiazolopyrimidine derivatives as MNKS inhibitors
    Patent number: 10669284
    Abstract: The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: June 2, 2020
    Assignee: LIFEARC
    Inventors: Jon James Winter-Holt, Edward Giles Mciver, Martin Ambler, Stephen Lewis, Joanne Osborne, Kayleigh Webb-Smith
  • Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors
    Publication number: 20180346483
    Abstract: The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease.
    Type: Application
    Filed: November 16, 2016
    Publication date: December 6, 2018
    Inventors: Jon James Winter-Holt, Edward Giles Mciver, Martin Ambler, Stephen Lewis, Joanne Osborne, Kayleigh Webb-Smith